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1. Introduction 
Generally speaking, Docking is most popular and critical issue in this research field, because 
it contains most important information both Ligands (Drugs) and Receptors (it can be 
intracellular protein, trans-membrane protein or extracellular protein). However, when the 
ligand’s information is not sufficient, it needs other calculation strategies to design and 
“modify” the ligands, and theoretically improve the drug effects, and that is called De Novo 
Evolution Drug Design. Current methods for structure-based drug design can be divided 
roughly into two categories. The first category is about “finding” ligands for a given 
receptor, which is usually referred as database searching. In this case, a large number of 
potential ligand molecules are screened to find those fitting the binding pocket of the 
receptor. This method is usually referred as structure-based drug design. The key advantage 
of database searching is that it saves synthetic effort to obtain new lead compounds. 
Another category of structure-based drug design methods is about “building” ligands, 
which is usually referred as receptor-based drug design. In this case, ligand molecules are 
built up within the constraints of the binding pocket by assembling small pieces in a 
stepwise manner. These pieces can be either individual atoms or molecular fragments. The 
key advantage of such a method is that novel structures, not contained in any database, can 
be suggested. These techniques are raising much excitement to the drug design community. 
Above two computational methods, the first is called virtual screening by Docking (the 
drugs are well prepared and need to be screen out the most suitable candidates), and the 
other is De.Novo Evolution Drug Design (De Novo means “creates” or “building” ligands) [1-
3]. However, when the targeting protein is unclear, or the factors are complicated, QSAR 
method is implemented to help user solving these problems. Because QSAR method just 
needs ligands structures and IC50 datasets to unveil an unknown novel drugs. Finally, when 
both of Ligands and Receptors are unknown, Homology Modeling is the only method for 
dealing with this problem. By using Homology Modeling, the Receptors 1-D sequences 
similarities can be used as a tool to reconstruct the 3-D structures. 
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2. Methods and materials 
Docking small molecules (ligands) into larger protein molecules (receptors) is a complex and 
difficult task. Docking programs include CDOCKER, LibDock, and LigandFit. Here, I 
introduce LigandFit for this research because it bases on an initial shape matched to the 
binding site and it is easier to observe the interaction of the ligand and the protein. 
There are two major parts of the LigandFit docking: 
1. Specify the region of the receptor to use as the binding site for docking. Site partitioning 
may be applied to select parts of the binding site during docking. 
2. Dock ligands to the specified site. This part consists of the following steps: 
a. Conformational search to generate candidate ligand conformations for docking; 
b. Compare the ligand shape and protein binding site shape by computing their size 
of possession; 
c. Minimize the rigid body energy of the candidate ligand pose/conformation by 
using the Dockscore calculation. 
In the following steps, we discard the water (because it will be complicated to the calculations) 
and ligand from the receptor protein, and calculate the score for the ligand docking to protein. 
Check the interacting force between the receptor protein and drugs (Fig. 1). 
 
Fig. 1. The procedure of LigandFit Docking procedure 
LigandFit: Docking and Score using Accelrys Software 
The score functions in the Discovery Studio 2.5 which we used were Dock Score, PLP1, PLP2 
and PMF. Candidate ligand poses are evaluated and prioritized according to the Dock Score 
function. There are two types of Dock Score. One is based on a force-field approximation, 
the other on the Piecewise Linear Potential function (PLP). 
 DockScore (forcefield) = - (ligand/receptor interaction energy + ligand internal energy) (1) 
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 DockScore(PLP) = - (PLP potential) (2) 
As shown in Equation1, there are two energy terms in the force-field version of Dock Score, 
internal energy of the ligand and the interaction energy of the ligand with the receptor. The 
interaction energy is taken as the sum of the van der Waals energy and electrostatic energy. 
The computation of the interaction energy can be quite time consuming. To reduce the time 
needed for this calculation, a grid-based estimation of the ligand/receptor interaction 
energy is employed [4]. 
The van der Waals component of the force-field interaction energy typically exhibits a steep 
rise at short interatomic distances, which can have undesirable consequences in the context 
of ligand-receptor docking. In particular, the combination of approximating the receptor 
structure as rigid and limited sampling of ligand conformational space tends to overly 
penalize poses with “mild” short contacts between the ligand and receptor, due to the 
“hard” nature of the van der Waals potential as defined in most standard force-fields. 
To overcome this tendency, a softened form of the van der Waals potential is employed with 
the Dock Score function. This softened potential rises to a large but finite value at zero 
interatomic separation. To maintain a proper balance between electrostatics and van der 
Waals, the electrostatic energy is also softened to prevent it from dominating the van der 
Waals energy at short separations.  
The internal energy of the ligand is computed when using the force-field version of Dock 
Score. The purpose of including the internal energy is to avoid ligand conformations with 
bad internal non-bond clashes. By default, only the standard (not softened) van der Waals 
energy is used for the ligand internal energy. Including electrostatic energy as part of the 
ligand internal energy is optionally available.  
The PLP version of Dock Score uses the PLP1 function, because the functional form of PLP1 
allows it to be readily represented with a grid-based approach. The PLP2 function has an 
angular dependence on hydrogen bonding interactions making its representation with a 
grid considerably more difficult. 
In the PLP1 score function, there are four atom types as following: (1) hydrogen bond donor 
only, (2) hydrogen bond acceptor only, (3) both hydrogen bond donor and acceptor, and (4) 
non-polar. When PLP1 is the docking scores function, the internal energy is calculated for 
each ligand conformation that the ligand is in the binding site [5]. 
In the PLP2 score function [6], the atom typing remains the same as in the PLP1 score 
function. In addition, an atomic radius is assigned to each atom expect for hydrogen [7]. 
The PMF score function was developed based on statistical analysis of the 3D structures of 
the protein-ligand complex [8]. They were found to correlate well with protein-ligand 
binding free energy while being fast and simple to calculate. The scores are calculated by 
summing pairwise interaction terms over all interatomic pairs of the receptor-ligand 
complex. The score function of Dock Score is the default function in the Discovery Studio 
2.5. 
All the simulations were also applied by CHARMM (Chemistry at Harvard Macromolecular 
Mechanics) Force-field. CHARMM was parameterized by experimental data. It has been 
used widely for simulations ranging from small molecules to solvated complexes of large 
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biological macromolecules. CHARMM performs well over a broad range of calculations and 
simulations, including minima, time-dependent dynamic behavior, and barriers to rotation, 
vibrational frequencies, and free energy. CHARMM uses a flexible and comprehensive 
energy function: 
( ) . intE Epot bond torsion oop elect vdW constra userE E E E E E        
Where, the out-of-plane (OOP) angle is an important torsion. The van der Waals term is 
derived from rare-gas potentials, and the electrostatic term can be scaled to mimic solvent 
effects. Hydrogen-bond energy is not included as a separate term as in AMBER. Instead, 
hydrogen-bond energy is implicit in the combination of van der Waals and electrostatic 
terms [9]. 
3. Research highlight 
In this section, I summarize some of my research works published in Journal of Life Sciences 
and IEEE International Conference on Bioinformatics and Bioengineering, which includes anti-
lung cancer and anti-oral cancer research, as illustrated as follows: 
3.1 Anti-lung cancer research 
The purpose of this research is to use computer docking and screening for the new type 
MEK1 inhibitor in lung cancer cells through the initiation of receptor tyrosine kinase and 
Mitogen-activated protein kinase pathway. The influence of lung cancer cell propagation 
suppressing by the combination of MEK protein and ATP was also discussed. A more active 
and potential drug molecule which can effectively lower the cost of developing lung cancer 
drugs can be proposed through the use of bioinformatics software and a series of data 
comparison, screening, and statistical analysis[10, 11].  
In this paper, “Computational Screening of Novel Mitogen-activated Protein Kinase Kinase-
1 (MEK1) Inhibitors by Docking and Scoring” [11], we discuss the MEK1 inhibitors by using 
LigandFit method to evaluate the affinity of the drug candidates (LIGANDS) towards the 
target Protein (Receptors, MEK1). The best docking poses analysis can be illustrated by Fig. 
2 [11]. In this figure, we can reveal which interaction forces are the critical roles in 
LIGANDS and Protein.  
There are several factors affecting the practical activity, such as the amino acids: LYS97, 
ASP190 in MEK protein, which are located at the entrance of the PROTEINs. When the 
LIGAND enter into the PROTEIN, some atoms of the LIGAND will bond to the entrance 
amino acids, moreover PHE209 which is at the terminal of the cavity will produce -
stacking force or H-BOND bonding, and the LIGANDs will not leave the PROTEINs. The 
LIGANDs of the high activity group almost have these characters, which will effectively 
inhibit the MEK PROTEIN. When talking about the LIGANDs of the low activity group, 
they enter a small way into the PROTEIN, and can easily leave the PROTEIN. PHE209 at 
the terminal of the cavity of the PROTEIN will affect the activity. The authors found the 
LIGAND of the high activity group had the aromatic group at the end of the molecule. So 
they would arise from the -stacking force. The medium activity LIGANDs formed a small-
stacking force. For the low activity LIGANDs, they would not form stacking force because 
they have no aromatic groups [11]. 
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Fig. 2.A PD184352 interacts with the PROTEIN and produces non-competitively with 
MgATP. It migrates into the PROTEIN and produces HBOND with MgATP and arouses a π 
stacking force with PHE209. PD184352 holds tightly with the PROTEIN and the MEK1 
PROTEIN will lose its function. [11] 
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Fig. 2.B This figure shows the location of the aromatic group of PHE209 and the aromatic 
group of PD13088. It reveals they probably have a π stacking force. [11] 
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3.2 Anti-oral cancer research 
This research paper “Predication the suppressing human oral cancer cell line by curcumin 
through the research of Fas receptor” [12] which is expected to calculate the activity of 
Curcumin to Fas receptor. Fas receptor is a key receptor which commonly mechanisms 
caused to oral cancer. The pharmaceutical activity are evaluate by the score from docking 
procedure perform by simulation program.  
The occurrence rate and death rate of oral cancer increased year by year according to the 
statistic value from Department of Health. The statistical report published by DOH in 2009 
indicates that the death rate of oral cancer rank number 6 in Taiwan among all 10 kinds of 
cancer and the occurrence rate rank number 4 in male among 10 kinds of cancer. These 
values persist very high in recent years. Tongue cancer and buccal cancer are the cancer 
with highest frequency in oral cancer. These two cancers take almost 90% of oral cancer and 
tongue cancer take 60% among all which is the highest. The effect of treating tongue cancer 
is far less than buccal cancer which makes the five year survival rate of oral cancer decrease 
gradually. Curcumin is able to activate the apoptosis pathway to make cancer cell apoptosis 
and achieve the anti-cancer effect. The purpose of this research is to simulate the 
pharmaceutical activity and evaluate the degree of activity to determine: (1) whether 
curcumin is able to activate cell apoptosis to oral cancer cells? (2) Is the pharmaceutical 
activity of curcumin to oral cancer cells higher than those medicines on market? 
Fas receptor (FasR) is a kind of death receptor on cell surface which can initiate the 
programmed cell death (cell apoptosis) through extrinsic pathway. Another one is the intrinsic 
pathway (mtirochondira). These are two types of cell apoptosis. FasR can also be called as 
CD95 which is the member of superfamilty of Apo-1 and TNF receptor [13, 14]. FasR is located 
on the 10th chromosome in human and 19th chromosome in rate. There are similar sequences in 
most mammal chromosomes [15]. The death-inducing signaling complex (DISC) formed by 
Fas can combine with receptor (FasL). FasL trimer makes the adjacent FasR to shape into 
trimer on the membrane and active the DISC below to attract and combine with Fas associsted 
death dimain(FADD). FADD will further attarct pro-caspase 8 for combination and cut the 
pro-caspase 8 into caspase 8. The caspase 8 will further cut and activate pro-caspase, therefore 
the caspase cascase magnifying effect is aroused to reinforce the activation of caspase 3. The 
caspase 3 will destruct the structural proteins such as cytokeletal protein and finish the 
apoptosis (reference: Eksp Klin Farmakol. 2010 Dec;73(12):44-9). 
Curcumin, which is a kind of yellowish pigment extract from roots of turmeric. 70% of 
Curcumin is composed of curcuminoid which takes 3%~6% of turmeric (http://curcumin-
turmeric.net/). The application of curcumin is far from now which curcumin were used as 
nature pigment in food industry. Beside, curcumin is stable to reductant and with good coloring 
ability but sensitive to light, heat and iron ions. The major application the coloring for canned 
food, sausages, and stewed soy sauce produce. Curcumin is also applied as acid-base indicator 
[pH 7.8 (yellow)- 9.2 (reddish brown)] (http://www.lookchem.cn/4150/productproperty.html). 
Curcumin have critical value and pharmaceutical action such as decreasing the blood fat, 
anti-oxidation, anti-inflammatory, and anti-atherosclerosis. Research in 2004 even found 
that curcumin can be use to suppress the activity of HIV-1 integrase and applied in AIDS 
clinical trial [16]. Beside the above functions, curcumin is also proved to have the 
pharmaceutical activity to anticancer and the effect of suppressing carcinoma have been 
verified repeatedly during many animal experiments [17, 18]. 
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This research is to calculate and simulate the pharmaceutical activity of anticancer effects of 
Curcumin to oral cancer and get quality evaluation results. The preliminary results are listed 
as figures and tables below. The receptor applied is curcumin-derivatives: bisdemethoxy 
curcumin; target protein: FAS/FADD death domain assembly (Protein PDB ID: 3OQ9) to 
perform Docking and Scoring: 
 
                       (a)                                                     (b)                                               (c) 
 
                                                   (d)                                                   (e) 
Fig. 3. (a) Bind Site-A & Ligand poses (I) (b) Bind Site-A & Ligand poses (III) (c) Bind Site-B 
& Ligand poses (I) (d) Bind Site-B & Ligand poses (II) (e) Bind Site-B & Ligand poses (III) 
 
Bind Site-A & Ligand poses (I) Bind Site-A & Ligand poses (III) Bind Site-B & Ligand poses (I) 
Name Index DOCK_SCORE Name Index DOCK_SCORE Name Index DOCK_SCORE 
Molecule-1 1 36.04 Molecule-1 1 24.895 Molecule-1 1 18.071 
Molecule-1 2 32.879 Molecule-1 2 17.943 Molecule-1 2 17.132 
Bind Site-B & Ligand poses (II) Bind Site-B & Ligand poses (III)  
Name Index DOCK_SCORE Name Index DOCK_SCORE 
Molecule-1 1 24.895 Molecule-1 1 39.984 
Molecule-1 2 17.943 Molecule-1 2 39.777 
Table 1. Docking Score data 
4. Conclusions 
In this chapter, I introduce the simple docking method: LigandFit. Without consider the 
water-containing environment (water free), and flexible situations (PROTEINs vibration), 
the estimations will be worthy of discussion. However, because of its fast screening and 
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effective for most Receptor cases, it can be applied to many anti-cancer drugs candidate 
virtual screening at many situations.  
5. Acknowledgement 
This work was supported by a grant from China Medical University (CMU95-173, CMU96-
107). The corresponding authors would like to thank their parents, all colleagues and friends 
who contributed to this study. We thank the editor and series editor for constructive 
criticisms and comments. 
6. References 
[1] Wang, R., Gao, Y., Lai, L. (2000), "LigBuilder: A Multi-Purpose Program for Structure-
Based Drug Design". Journal of Molecular Modeling 6 (7-8): 498–516.  
[2] Schneider, G., Fechner, U. (2005), "Computer-based de novo design of drug-like 
molecules". Nat Rev Drug Discov 4 (8): 649–663. 
[3] Jorgensen, W. L. (2004), "The many roles of computation in drug discovery". Science 303 
(5665): 1813–1818.  
[4] Venkatachalam, C. M., Jiang, X., Oldfield, T. Waldman, M. (2003), “LigandFit: a novel 
method for the shape-directed rapid docking of ligands to protein active sites”. 
Journal of Molecular Graphics and Modelling. 21(4), 289-307. 
[5] Gehlhaar, D. K., Verkhivker, G. M., Rejto, P. A., Sherman, C. J., Fogel, D. B., Fogel, L. J., 
Freer, S. T. (1995), “Molecular Recognition of the Inhibitor AG-1343 by HIV-1 
Protease: Conformationally Flexible Docking by Evolutionary Programming”. 
Chemistry & Biology 2, 317. 
[6] Gehlhaar, D. K., Bouzida, D., Rejto, P. A. (1999). Rational Drug Design: Novel Methodology 
and Practical Applications ; Parrill, L.; Rami Reddy, M; Series title: ACS symposium 
series, 719; American Chemical Society: Washington, DC., 292-311. 
[7] Bouzida, D., Arthurs S., et al, (1999). Thermodynamics and kinetics of ligand-protein 
binding studied with the weighted histogram analysis method and simulated 
annealing, Pac Symp Biocomput, , 426-437. 
[8] Muegge, I. and Martin, Y. C. (1999), “A general and fast scoring function for protein-
ligand interactions: a simplified potential approach”, J Med Chem, 42, 791-804. 
[9] Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., Karplus, M. 
(1983), "CHARMM: A program for macromolecular energy, minimization, and 
dynamics calculations". J Comp Chem 4 (2): 187–217. 
[10] Chen, P. Y., Jhuo, M. D., Hsu, W. T., Shih, T. C., Cheng T. H., (2009), “The MAPK Signal 
Pathway Research and New Drug Discovery”, 2009 Ninth IEEE International 
Conference on Bioinformatics and Bioengineering, 370-373. 
[11] Chen, P. Y., Hong, H. J., Jhuo, M. D., Cheng, T. H., Hsu, W. T., Wu, C. H., Ou, C. Y., Yui, 
Y. T., Lin, J. P., Chung, J. G., (2011), “Computational Screening of Novel Mitogen-
activated Protein Kinase Kinase-1(MEK1) Inhibitors by Docking and Scoring”, 
Journal of Life Sciences, 5, 434-442. 
[12] Chen, P. Y., Wu, Y. C., Cheng, T. H., Shih, T. C., Tsai, C. T., Wu, C. H., Hua, T. Y. 
Huang, Y. Y., Cheng, C. H., Fan, M. J. (2011), “Predication the suppressing human 
oral cancer cell line by curcumin through the research of Fas receptor”, 2011 Ninth 
IEEE International Conference on Bioinformatics and Bioengineering, accepted. 
www.intechopen.com
 
Virtual Screening 
 
100 
[13] Neumann, L., Pforr, C., Beaudouin, J., Pappa, A., Fricker, N., Krammer, P.H., Lavrik, 
I.N., Eils, R. (2010). “Dynamics within the CD95 death-inducing signaling complex 
decide life and death of cells”, Molecular Systems Biology. 6, 352. 
[14] Nagata, S. (1997), “Apoptosis by death factor”, Cell. 88, 355-65. 
[15] Cascino, I., Papoff, G., Eramo, A., Ruberti, G. (1996), “Soluble Fas/Apo-1 splicing 
variants and apoptosis”, Frontiers in Bioscience. 1, d12-8. 
[16] Padma TV. Turmeric can combat malaria, cancer virus and HIV. SciDev.net. 2005-03-11 
[17] Aggarwal, B. B., Shshodia, S. (2006), “Molecular targets of dietary agents for prevention 
and therapy of cancer”, Biochemical Pharmacology- Elsevier. 71, 1397–421. 
[18] Choi, H., Chun, Y.S., Kim, S.W., Kim, M.S., Park, J. W.. (2006), “Curcumin Inhibits 
Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear 
Translocator: A Mechanism of Tumor Growth Inhibition. Molecular Pharmacology”, 
American Society for Pharmacology and Experimental Therapeutics. 70, 1664–71. 
www.intechopen.com
Virtual Screening
Edited by Prof. Mutasem Taha
ISBN 978-953-51-0308-0
Hard cover, 100 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Pharmacophore modeling, QSAR analysis, CoMFA, CoMSIA, docking and molecular dynamics simulations,
are currently implemented to varying degrees in virtual screening towards discovery of new bioactive hits.
Implementation of such techniques requires multidisciplinary knowledge and experience. This volume
discusses established methodologies as well as new trends in virtual screening with aim of facilitating their use
in drug discovery.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Po-Yuan Chen (2012). Computational Virtual Screening Towards Designing Novel Anticancer Drugs, Virtual
Screening, Prof. Mutasem Taha (Ed.), ISBN: 978-953-51-0308-0, InTech, Available from:
http://www.intechopen.com/books/virtual-screening/computational-virtual-screening-of-antivirus-and-
anticancer-drugs-design
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
